FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer’s Disease with…
Biogen and Eisai, Co., Ltd. (Tokyo, Japan) announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for aducanumab, an…
Read More...
Read More...
